Cargando…
Metronomic chemotherapy and anti-angiogenesis: can upgraded pre-clinical assays improve clinical trials aimed at controlling tumor growth?
Metronomic chemotherapy, which is continuously administered systemically at close to non-toxic doses, targets the endothelial cells (ECs) that are proliferating during tumor angiogenesis. This leads to harmful effects of an even greatly increased number contiguous tumor cells. Although pre-clinical...
Autor principal: | Norrby, Klas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282375/ https://www.ncbi.nlm.nih.gov/pubmed/24164171 http://dx.doi.org/10.1111/apm.12201 |
Ejemplares similares
-
Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis
por: ALBERTSSON, PER, et al.
Publicado: (2012) -
Rat Mesentery Angiogenesis Assay
por: Norrby, Klas C.
Publicado: (2011) -
Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting
por: Petrizzo, Annacarmen, et al.
Publicado: (2017) -
Metronomic chemotherapy
por: Maiti, Rituparna
Publicado: (2014) -
Metronomic Chemotherapy
por: Cazzaniga, Marina Elena, et al.
Publicado: (2021)